Drugs show promise for childhood brain tumors, ovarian cancer

An experimental drug has shown promise in treating malignant brain tumors in children, a small study unveiled at the annual American Society of Clinical Oncology conference showed Sunday.

The early stage trial tested the effects of GDC-0449 on drug-resistant medulloblastomas, the most common form of brain tumor found in children.

Developed by US biotech firms Curis and Genentec, the latter owned by Swiss pharmaceutical group Roche since 2009, the drug works by blocking the so-called "Hedgehog" pathway.

The pathway is key to regulating cell growth and is implicated in around 20 percent of medulloblastomas, as well as other cancers.

The trial involved just 13 children, 12 of whom tolerated the drug without any significant side effects. One of the children in the trial went a year on the drug without any tumor progression.

In a previous case, a young adult with medulloblastoma experienced a similarly positive result, according to Amar Gajjar, director of the Neuro-Oncology Division at St. Jude's Children's Research Hospital in Tennessee and lead investigator in the research.

"Some patients have remained on this trial for extended periods of time, and our early results are positive and encouraging," he said at a press conference during the annual meeting of cancer researchers.

"The trend in treating children with these cancers is toward targeted therapies like this one, which block key signaling pathways and disable the cancer's ability to function or reproduce," he added.

Another study presented Sunday showed new ways to slow the return of certain types of ovarian cancer in women who have undergone chemotherapy.

The research analyzed the effect of giving a drug called Avastin to women suffering from advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer.

The drug, known generically as bevacizumab, works by blocking the development of blood vessels that can promote tumor growth.

"This is the first time a Phase III trial has demonstrated that an anti-angiogenic agent improved progression-free survival in women with this very hard-to-treat-disease," said Robert Burger of the Fox Chase Cancer Center in Philadelphia, who led the research.

"Based on the results of this... trial, bevacizumab is an acceptable initial treatment option for patients with advanced ovarian, primary peritoneal and fallopian tube cancers," said Burger.

Avastin is sold by US firm Genetech, part of Swiss pharmaceutical group Roche and has already been authorized by the US Food and Drug Administration for use in treating cancers including colon, breast, kidney, brain and lung.

Previous small-scale clinical studies involving Avastin had shown the drug's potential for ovarian cancer patients, but this trial involved an international pool of 1,873 women with newly-diagnosed advanced stage ovarian, primary peritoneal or fallopian tube cancer.

The women had all undergone surgery to remove as much of the tumor as possible, and were assigned to one of three groups.

The first received standard chemotherapy supplemented with a placebo and then received a placebo for follow-up medicine; the second received chemotherapy plus Avastin and a placebo follow-up drug; the third received chemotherapy plus Avastin and also took Avastin to follow-up.

Those in the final group had a median recurrence-free survival rate of 14.1 months, compared with the 10.3 month rate among those who received chemotherapy alone - a statistically significant difference.

The difference between the third group and those who only took Avastin during chemotherapy was judged statistically insignificant.

Ovarian cancer affects some 230,000 women each year, killing around 140,000. It is the eighth most deadly cancer among women.

Life and Style
ebookNow available in paperback
ebooks
ebookA delicious collection of 50 meaty main courses
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Recruitment Genius: Home Care / Support Workers

    £7 - £10 per hour: Recruitment Genius: This care provider is looking for Home ...

    Recruitment Genius: Web Team Leader

    £30000 - £35000 per annum: Recruitment Genius: One of the UK's leading web des...

    Recruitment Genius: Client Manager

    £27000 - £35000 per annum: Recruitment Genius: A growing, successful, friendly...

    Recruitment Genius: Property Negotiator - OTE £20,000+

    £16000 - £25000 per annum: Recruitment Genius: This family owned, independent ...

    Day In a Page

    Greece says 'No': A night of huge celebrations in Athens as voters decisively back Tsipras and his anti-austerity stance in historic referendum

    Greece referendum

    Greeks say 'No' to austerity and plunge Europe into crisis
    Ten years after the 7/7 terror attacks, is Britain an altered state?

    7/7 bombings anniversary

    Ten years after the terror attacks, is Britain an altered state?
    Beautiful evening dresses are some of the loveliest Donatella has created

    Versace haute couture review

    Beautiful evening dresses are some of the loveliest Donatella has ever created
    No hope and no jobs, so Gaza's young risk their lives, climb the fence and run for it

    No hope and no jobs in Gaza

    So the young risk their lives and run for it
    Fashion apps: Retailers roll together shopping and social networking for mobile customers

    Fashion apps

    Retailers roll together shopping and social networking for mobile customers
    The Greek referendum exposes a gaping hole at the heart of the European Union – its distinct lack of any genuine popular legitimacy

    Gaping hole at the heart of the European Union

    Treatment of Greece has shown up a lack of genuine legitimacy
    Number of young homeless in Britain 'more than three times the official figures'

    'Everything changed when I went to the hostel'

    Number of young homeless people in Britain is 'more than three times the official figures'
    Compton Cricket Club

    Compton Cricket Club

    Portraits of LA cricketers from notorious suburb to be displayed in London
    London now the global money-laundering centre for the drug trade, says crime expert

    Wlecome to London, drug money-laundering centre for the world

    'Mexico is its heart and London is its head'
    The Buddhist temple minutes from Centre Court that helps a winner keep on winning

    The Buddhist temple minutes from Centre Court

    It helps a winner keep on winning
    Is this the future of flying: battery-powered planes made of plastic, and without flight decks?

    Is this the future of flying?

    Battery-powered planes made of plastic, and without flight decks
    Isis are barbarians – but the Caliphate is a dream at the heart of all Muslim traditions

    Isis are barbarians

    but the Caliphate is an ancient Muslim ideal
    The Brink's-Mat curse strikes again: three tons of stolen gold that brought only grief

    Curse of Brink's Mat strikes again

    Death of John 'Goldfinger' Palmer the latest killing related to 1983 heist
    Greece debt crisis: 'The ministers talk to us about miracles' – why Greeks are cynical ahead of the bailout referendum

    'The ministers talk to us about miracles'

    Why Greeks are cynical ahead of the bailout referendum
    Call of the wild: How science is learning to decode the way animals communicate

    Call of the wild

    How science is learning to decode the way animals communicate